PULSE BIOSCIENCES, INC. (PLSE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74587B1017
PULSE BIOSCIENCES, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 350,000.00 USD |
| Gross profit | -189,000.00 USD |
| Operating income | -76.94 m USD |
| EBIT | -72.78 m USD |
| Net income | -72.78 m USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PULSE BIOSCIENCES, INC.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
More stocks
- Credit Saison Co Ltd (8253.T)
- Madison Square Garden Entertainment Corp. (MSGE)
- Iida Group Holdings Co Ltd (3291.T)
- Caihong Display Devices Co Ltd (600707.SS)
- Accelerant Holdings (ARX)
- Parq Arauco (PARAUCO.SN)
- Jet2 PLC (JET2.L)
- Granite Real Estate Investment Trust (GRTUF)
- S N Nuclearele (SNN.RO)
- Serco Group PLC (SRP.L)
- East Buy Holding Ltd (1797.HK)
- XtalPi Holdings Ltd (2228.HK)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.